Cogent Biosciences, Inc. COGT
We take great care to ensure that the data presented and summarized in this overview for Cogent Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding COGT
View all-
Kynam Capital Management, LP Princeton, NJ9.11MShares$85.1 Million4.6% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY8.96MShares$83.8 Million2.75% of portfolio
-
Commodore Capital LP New York, NY8.89MShares$83.1 Million5.22% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$68.1 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$65.1 Million10.05% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA6.23MShares$58.2 Million12.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.06MShares$56.6 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY5.68MShares$53.1 Million8.22% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.3MShares$49.5 Million0.08% of portfolio
-
State Street Corp Boston, MA4.12MShares$38.5 Million0.0% of portfolio
Latest Institutional Activity in COGT
Top Purchases
Top Sells
About COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at COGT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2025
|
Fairmount Funds Management LLC Director |
BUY
Open market or private purchase
|
Indirect |
2,777,777
+23.58%
|
$24,999,993
$9.0 P/Share
|
|
Jan 14
2025
|
Cole Pinnow Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
43,750
+48.83%
|
$306,250
$7.6 P/Share
|
|
Jun 10
2024
|
Fairmount Funds Management LLC Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,500,000
+19.42%
|
-
|
|
Mar 28
2024
|
Fairmount Funds Management LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
286,851
+5.72%
|
-
|
|
Mar 28
2024
|
Fairmount Funds Management LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
286,851
-100.0%
|
-
|
|
Feb 16
2024
|
Fairmount Funds Management LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,166,666
+20.81%
|
$8,166,662
$7.5 P/Share
|
|
Jun 09
2023
|
Fairmount Funds Management LLC Director |
BUY
Open market or private purchase
|
Indirect |
800,000
+19.65%
|
$9,600,000
$12.0 P/Share
|
|
Jun 30
2022
|
Jessica Sachs Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
622
+50.0%
|
$4,354
$7.39 P/Share
|
|
Jun 16
2022
|
Fairmount Funds Management LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,200,000
+32.68%
|
$9,600,000
$8.25 P/Share
|
|
Dec 31
2021
|
Jessica Sachs Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
674
+50.0%
|
$4,044
$6.82 P/Share
|
|
Apr 26
2021
|
John L. Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
17,813
-82.26%
|
$142,504
$8.86 P/Share
|
|
Feb 25
2021
|
John L. Green Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
524
+2.36%
|
-
|
|
Dec 01
2020
|
John L. Green Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,748
+50.0%
|
-
|
|
Jul 06
2020
|
Fairmount Funds Management LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
6,235,903
+50.0%
|
-
|
|
May 12
2020
|
Dario Campana > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
98,200
-3.08%
|
$0
$0.46 P/Share
|
|
May 11
2020
|
Dario Campana > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-1.53%
|
$0
$0.46 P/Share
|
|
May 08
2020
|
Dario Campana > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-2.95%
|
$0
$0.46 P/Share
|
|
May 07
2020
|
Dario Campana > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-2.86%
|
$0
$0.41 P/Share
|
|
May 06
2020
|
Dario Campana > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,800
-0.05%
|
$0
$0.4 P/Share
|
|
May 05
2020
|
Dario Campana > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
135,484
-3.73%
|
$0
$0.4 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 2.82M shares |
|---|